PTK2/FAK: a new predictive biomarker for response to radiotherapy in head and neck squamous cell carcinoma

Affiliations

Comment

Emma J de Ruiter et al. Ann Transl Med. 2016 Oct.

. 2016 Oct;4(Suppl 1):S44.

doi: 10.21037/atm.2016.10.19.

No abstract available

Conflict of interest statement

The authors have no conflicts of interest to declare.

Proteomic Profiling Identifies PTK2/FAK as a Driver of Radioresistance in HPV-negative Head and Neck Cancer.
Skinner HD, Giri U, Yang L, Woo SH, Story MD, Pickering CR, Byers LA, Williams MD, El-Naggar A, Wang J, Diao L, Shen L, Fan YH, Molkentine DP, Beadle BM, Meyn RE, Myers JN, Heymach JV. Skinner HD, et al. Clin Cancer Res. 2016 Sep 15;22(18):4643-50. doi: 10.1158/1078-0432.CCR-15-2785. Epub 2016 Apr 1. Clin Cancer Res. 2016. PMID: 27036135 Free PMC article.

1. Argiris A, Karamouzis MV, Raben D, et al. Head and neck cancer. Lancet 2008;371:1695-709. 10.1016/S0140-6736(08)60728-X - DOI - PMC - PubMed
1. Murdoch D. Standard, and novel cytotoxic and molecular-targeted, therapies for HNSCC: an evidence-based review. Curr Opin Oncol 2007;19:216-21. 10.1097/01.cco.0000264952.98166.99 - DOI - PubMed
1. Ang KK, Zhang Q, Rosenthal DI, et al. Randomized phase III trial of concurrent accelerated radiation plus cisplatin with or without cetuximab for stage III to IV head and neck carcinoma: RTOG 0522. J Clin Oncol 2014;32:2940-50. 10.1200/JCO.2013.53.5633 - DOI - PMC - PubMed
1. Kimple RJ, Smith MA, Blitzer GC, et al. Enhanced radiation sensitivity in HPV-positive head and neck cancer. Cancer Res 2013;73:4791-800. 10.1158/0008-5472.CAN-13-0587 - DOI - PMC - PubMed
1. Swartz JE, Pothen AJ, Stegeman I, et al. Clinical implications of hypoxia biomarker expression in head and neck squamous cell carcinoma: a systematic review. Cancer Med 2015;4:1101-16. 10.1002/cam4.460 - DOI - PMC - PubMed